Drug interactions between Incruse Ellipta and Spiriva
|Incruse Ellipta (umeclidinium)|
Interactions between your drugs
Applies to: Spiriva (tiotropium) and Incruse Ellipta (umeclidinium)
Using tiotropium together with umeclidinium may increase side effects such as drowsiness, blurred vision, dry mouth, heat intolerance, flushing, decreased sweating, difficulty urinating, abdominal cramping, constipation, rapid heart beat, confusion, memory problems, and glaucoma. Although serious side effects are not very common with inhaled or topically applied preparations because only limited amounts of the medication generally get absorbed into the bloodstream from the lungs or skin, they can sometimes occur, especially in the elderly or when combined with other medications that have similar side effects. Talk to your doctor if you have any questions or concerns. Your doctor may be able to prescribe alternatives that do not interact. You should avoid activities requiring mental alertness such as driving or operating hazardous machinery until you know how these medications affect you. When using an inhaled product, try keeping your eyes closed or using an eye mask to avoid having the medication get into the eyes. When using a topical preparation such as a cream or solution, avoid applying to broken skin or using occlusive dressings over the application areas, and also avoid touching the eyes until after you wash your hands with soap and water. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Drug and food interactions
No results found in our database - however, this does not necessarily mean no interactions exist. Always consult with your doctor or pharmacist.
Therapeutic duplication warnings
Therapeutic duplication is the use of more than one medicine from the same drug category or therapeutic class to treat the same condition. This can be intentional in cases where drugs with similar actions are used together for demonstrated therapeutic benefit. It can also be unintentional in cases where a patient has been treated by more than one doctor, or had prescriptions filled at more than one pharmacy, and can have potentially adverse consequences.
The recommended maximum number of medicines in the 'anticholinergics/antispasmodics' category to be taken concurrently is usually one. Your list includes two medicines belonging to the 'anticholinergics/antispasmodics' category:
- Incruse Ellipta (umeclidinium)
- Spiriva (tiotropium)
Note: The benefits of taking this combination of medicines may outweigh any risks associated with therapeutic duplication. This information does not take the place of talking to your doctor. Always check with your healthcare provider to determine if any adjustments to your medications are needed.
Drug Interaction Classification
|Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.|
|Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.|
|Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.|
|No information available.|
Do not stop taking any medications without consulting your healthcare provider.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.